Atara Biotherapeutics(US:ATRA) ZACKS·2024-11-12 23:16Financial Performance - Atara Biotherapeutics reported a quarterly loss of $2.93 per share, which was better than the Zacks Consensus Estimate of a loss of $3.77, and a significant improvement from a loss of $16.50 per share a year ago, indicating an earnings surprise of 22.28% [1] - The company posted revenues of $40.19 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 74.74%, compared to revenues of $2.14 million in the same quarter last year [2] Stock Performance - Atara Biotherapeutics shares have declined approximately 8.2% since the beginning of the year, while the S&P 500 has gained 25.8% [3] - The current Zacks Rank for Atara Biotherapeutics is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$5.65 on revenues of $13.1 million, and for the current fiscal year, it is -$12.09 on revenues of $92.1 million [7] - The trend of estimate revisions for Atara Biotherapeutics is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Atara Biotherapeutics belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]